African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker.
Didier LeroyFiona MacintyreYeka AdokeSerge OuobaAissata BarryGhyslain Mombo-NgomaJacques Mari Ndong NgomoRosauro VaroYannelle DossouAntoinette Kitoto TshefuTran Thanh DuongBui Quang PhucBart LaurijssensRoland KlopperNimol KhimEric LegrandDidier MénardPublished in: Malaria journal (2019)
These findings were considered to sharply contrast with the recent description of increased sensitivity to PPQ of Ugandan parasite isolates. This emphasizes the necessity to investigate in vitro susceptibility profiles to PPQ of African isolates with multiple copies of the Pfpm2 gene and estimate the risk of development of PPQ resistance in Africa. Trial registration Clinicaltrials.gov reference: NCT02083380. Study title: Phase II efficacy study of artefenomel and piperaquine in adults and children with P. falciparum malaria. https://clinicaltrials.gov/ct2/results?cond=&term=NCT02083380&cntry=&state=&city=&dist= . FSFV: 23-Jul-2014; LSLV: 09-Oct-2015.
Keyphrases
- plasmodium falciparum
- phase ii
- clinical trial
- magnetic resonance
- genetic diversity
- phase iii
- genome wide
- copy number
- dna methylation
- computed tomography
- young adults
- magnetic resonance imaging
- gene expression
- study protocol
- image quality
- positron emission tomography
- genome wide identification
- placebo controlled
- genome wide analysis